Effect of a multicomponent quality improvement strategy on sustained achievement of diabetes care goals and macrovascular and microvascular complications in South Asia at 6.5 years follow-up: Post hoc analyses of the CARRS randomized clinical trial.

Autor: Ali MK; Department of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, Georgia, United States of America.; Emory Global Diabetes Research Center, Woodruff Health Sciences Center, Emory University, Atlanta, Georgia, United States of America., Singh K; Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.; Public Health Foundation of India, Gurgaon, India., Kondal D; Centre for Chronic Disease Control, New Delhi, India., Devarajan R; Public Health Foundation of India, Gurgaon, India., Patel SA; Department of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, Georgia, United States of America.; Emory Global Diabetes Research Center, Woodruff Health Sciences Center, Emory University, Atlanta, Georgia, United States of America.; Emory University, Rollins School of Public Health, Atlanta, Georgia, United States of America., Menon VU; Amrita Institute of Medical Sciences, Department of Endocrinology & Diabetes, AIMS Ponekkara, Kochi, India., Varthakavi PK; TNM College & BYL Nair Charity Hospital, Department of Endocrinology, Mumbai, India., Vishwanathan V; MV Hospital for Diabetes & Diabetes Research Centre, Chennai, India., Dharmalingam M; Bangalore Endocrinology & Diabetes Research Centre, Bangalore, India., Bantwal G; St. John's Medical College & Hospital, Department of Endocrinology, Bangalore, India., Sahay RK; Osmania General Hospital, Department of Endocrinology, Hyderabad, India., Masood MQ; Aga Khan University, Department of Medicine, Section of Endocrinology and Diabetes, Karachi, Pakistan., Khadgawat R; All India Institute of Medical Sciences, Department of Endocrinology & Metabolism, Biotechnology Block, New Delhi, India., Desai A; Goa Medical College, Department of Endocrinology, Bambolim, India., Prabhakaran D; Centre for Chronic Disease Control, New Delhi, India.; Centre for Control of Chronic Conditions, Public Health Foundation of India, Gurgaon, India., Narayan KMV; Emory Global Diabetes Research Center, Woodruff Health Sciences Center, Emory University, Atlanta, Georgia, United States of America., Tandon N; All India Institute of Medical Sciences, Department of Endocrinology & Metabolism, Biotechnology Block, New Delhi, India.
Jazyk: angličtina
Zdroj: PLoS medicine [PLoS Med] 2024 Jun 03; Vol. 21 (6), pp. e1004335. Date of Electronic Publication: 2024 Jun 03 (Print Publication: 2024).
DOI: 10.1371/journal.pmed.1004335
Abstrakt: Background: Diabetes control is poor globally and leads to burdensome microvascular and macrovascular complications. We aimed to assess post hoc between-group differences in sustained risk factor control and macrovascular and microvascular endpoints at 6.5 years in the Center for cArdiovascular Risk Reduction in South Asia (CARRS) randomized trial.
Methods and Findings: This parallel group individual randomized clinical trial was performed at 10 outpatient diabetes clinics in India and Pakistan from January 2011 through September 2019. A total of 1,146 patients with poorly controlled type 2 diabetes (HbA1c ≥8% and systolic BP ≥140 mm Hg and/or LDL-cholesterol ≥130 mg/dL) were randomized to a multicomponent quality improvement (QI) strategy (trained nonphysician care coordinator to facilitate care for patients and clinical decision support system for physicians) or usual care. At 2.5 years, compared to usual care, those receiving the QI strategy were significantly more likely to achieve multiple risk factor control. Six clinics continued, while 4 clinics discontinued implementing the QI strategy for an additional 4-year follow-up (overall median 6.5 years follow-up). In this post hoc analysis, using intention-to-treat, we examined between-group differences in multiple risk factor control (HbA1c <7% plus BP <130/80 mm Hg and/or LDL-cholesterol <100 mg/dL) and first macrovascular endpoints (nonfatal myocardial infarction, nonfatal stroke, death, revascularization [angioplasty or coronary artery bypass graft]), which were co-primary outcomes. We also examined secondary outcomes, namely, single risk factor control, first microvascular endpoints (retinopathy, nephropathy, neuropathy), and composite first macrovascular plus microvascular events (which also included amputation and all-cause mortality) by treatment group and whether QI strategy implementation was continued over 6.5 years. At 6.5 years, assessment data were available for 854 participants (74.5%; n = 417 [intervention]; n = 437 [usual care]). In terms of sociodemographic and clinical characteristics, participants in the intervention and usual care groups were similar and participants at sites that continued were no different to participants at sites that discontinued intervention implementation. Patients in the intervention arm were more likely to exhibit sustained multiple risk factor control than usual care (relative risk: 1.77; 95% confidence interval [CI], 1.45, 2.16), p < 0.001. Cumulatively, there were 233 (40.5%) first microvascular and macrovascular events in intervention and 274 (48.0%) in usual care patients (absolute risk reduction: 7.5% [95% CI: -13.2, -1.7], p = 0.01; hazard ratio [HR] = 0.72 [95% CI: 0.61, 0.86]), p < 0.001. Patients in the intervention arm experienced lower incidence of first microvascular endpoints (HR = 0.68 [95% CI: 0.56, 0.83), p < 0.001, but there was no evidence of between-group differences in first macrovascular events. Beneficial effects on microvascular and composite vascular outcomes were observed in sites that continued, but not sites that discontinued the intervention.
Conclusions: In urban South Asian clinics, a multicomponent QI strategy led to sustained multiple risk factor control and between-group differences in microvascular, but not macrovascular, endpoints. Between-group reductions in vascular outcomes at 6.5 years were observed only at sites that continued the QI intervention, suggesting that practice change needs to be maintained for better population health of people with diabetes.
Trial Registration: ClinicalTrials.gov NCT01212328.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: MKA has received research support (to Emory University) from Merck and consulting fees from Bayer and Eli Lilly, all outside the scope of this work. SP received research funding in the area of CVD implementation sciences. All other authors have declared that no competing interests exist.
(Copyright: © 2024 Ali et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje